CD133 has also been identified as a lung CSC marker; notably, CD133+ cells have sphere-forming and tumorigenic capabilities [84], are chemoresistant, and are a biomarker of poor prognosis in lung cancer patients [82]. Here, PROM1 is linked to lung carcinoma.